Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 206
9
Diseases
25
Unique genes
0.333
Avg. similarity score
Appendix neuroendocrine tumor g1
Most-connected disease (7 links)
Disease
Searched: Ovarian microcystic stromal tumor
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Ovarian microcystic stromal tumor
Appendix neuroendocrine tumor g1
Desmoid tumor
Desmoplastic fibroma
Rectal traditional serrated adenoma
Angiofibroma
Intestinal neoplasms
Ovarian mixed epithelial tumor
Oligodontia-cancer predisposition syndrome
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Appendix neuroendocrine tumor g1 | 7 | 7 | 4 |
| Desmoid tumor | 7 | 7 | 3 |
| Desmoplastic fibroma | 7 | 7 | 2 |
| Ovarian microcystic stromal tumor | 7 | 7 | 3 |
| Rectal traditional serrated adenoma | 7 | 7 | 7 |
| Angiofibroma | 6 | 6 | 5 |
| Intestinal neoplasms | 5 | 5 | 12 |
| Ovarian mixed epithelial tumor | 5 | 5 | 6 |
| Oligodontia-cancer predisposition syndrome | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| APC | 8 / 9 | Angiofibroma, Appendix neuroendocrine tumor g1, Desmoid tumor, Desmoplastic fibroma and 4 more |
| CTNNB1 | 8 / 9 | Angiofibroma, Appendix neuroendocrine tumor g1, Desmoid tumor, Desmoplastic fibroma and 4 more |
| TP53 | 3 / 9 | Appendix neuroendocrine tumor g1, Ovarian mixed epithelial tumor, Rectal traditional serrated adenoma |
| AXIN2 | 2 / 9 | Angiofibroma, Oligodontia-cancer predisposition syndrome |
| KRAS | 2 / 9 | Ovarian microcystic stromal tumor, Rectal traditional serrated adenoma |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Endometrial cancer | KEGG | 10 / 59 | 81.4× | 1.13e-17 | 5.80e-15 ✓ sig. |
| Gastric cancer | KEGG | 12 / 150 | 38.4× | 4.17e-17 | 1.89e-14 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 12 / 170 | 33.9× | 1.94e-16 | 7.66e-14 ✓ sig. |
| Colorectal cancer | KEGG | 10 / 87 | 55.2× | 6.99e-16 | 2.49e-13 ✓ sig. |
| Human papillomavirus infection | KEGG | 13 / 333 | 18.8× | 1.75e-14 | 4.75e-12 ✓ sig. |
| Breast cancer | KEGG | 10 / 148 | 32.5× | 1.66e-13 | 3.67e-11 ✓ sig. |
| Prostate cancer | KEGG | 9 / 98 | 44.1× | 2.02e-13 | 4.42e-11 ✓ sig. |
| Endocrine resistance | KEGG | 9 / 99 | 43.7× | 2.22e-13 | 4.81e-11 ✓ sig. |
| Pathways in cancer | KEGG | 14 / 533 | 12.6× | 2.76e-13 | 5.82e-11 ✓ sig. |
| Glioma | KEGG | 8 / 76 | 50.6× | 1.75e-12 | 3.14e-10 ✓ sig. |
| Human cytomegalovirus infection | KEGG | 10 / 226 | 21.3× | 1.17e-11 | 1.74e-9 ✓ sig. |
| AGE-RAGE signaling pathway in diabetic complications | KEGG | 8 / 101 | 38.1× | 1.81e-11 | 2.59e-9 ✓ sig. |
| Hepatitis B | KEGG | 9 / 163 | 26.5× | 2.12e-11 | 2.98e-9 ✓ sig. |
| Sphingolipid signaling pathway | KEGG | 8 / 122 | 31.5× | 8.42e-11 | 1.01e-8 ✓ sig. |
| Thyroid cancer | KEGG | 6 / 37 | 77.9× | 9.48e-11 | 1.12e-8 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| negative regulation of cell population proliferation | GO:0008285 | 12 / 444 | 20.2× | 1.10e-13 | 6.28e-11 ✓ sig. |
| regulation of cell cycle | GO:0051726 | 7 / 262 | 20.0× | 3.81e-8 | 5.60e-6 ✓ sig. |
| response to gamma radiation | GO:0010332 | 4 / 27 | 111× | 4.28e-8 | 6.22e-6 ✓ sig. |
| negative regulation of mitotic cell cycle | GO:0045930 | 4 / 28 | 107× | 4.99e-8 | 7.06e-6 ✓ sig. |
| heart development | GO:0007507 | 7 / 273 | 19.2× | 5.05e-8 | 7.14e-6 ✓ sig. |
| negative regulation of neuron apoptotic process | GO:0043524 | 6 / 160 | 28.0× | 5.55e-8 | 7.73e-6 ✓ sig. |
| apoptotic signaling pathway | GO:0097190 | 5 / 84 | 44.5× | 8.05e-8 | 1.06e-5 ✓ sig. |
| negative regulation of apoptotic signaling pathway | GO:2001234 | 4 / 36 | 83.1× | 1.43e-7 | 1.72e-5 ✓ sig. |
| response to salt stress | GO:0009651 | 3 / 9 | 249× | 1.77e-7 | 2.04e-5 ✓ sig. |
| negative regulation of cyclin-dependent protein serine/threonine kinase activity | GO:0045736 | 3 / 9 | 249× | 1.77e-7 | 2.04e-5 ✓ sig. |
| T cell differentiation in thymus | GO:0033077 | 4 / 41 | 72.9× | 2.44e-7 | 2.67e-5 ✓ sig. |
| DNA damage response | GO:0006974 | 8 / 577 | 10.4× | 5.35e-7 | 5.16e-5 ✓ sig. |
| intrinsic apoptotic signaling pathway in response to DNA damage | GO:0008630 | 4 / 54 | 55.4× | 7.53e-7 | 6.80e-5 ✓ sig. |
| response to UV | GO:0009411 | 4 / 54 | 55.4× | 7.53e-7 | 6.80e-5 ✓ sig. |
| stem cell proliferation | GO:0072089 | 4 / 54 | 55.4× | 7.53e-7 | 6.80e-5 ✓ sig. |